摘要
目的研究苦参素胶囊在慢性乙肝患者体内的药代动力学,比较其在慢性乙肝患者及健康受试者的药代动力学差异,以指导临床用药。方法10例慢性乙肝患者和10例健康受试者分别单次口服苦参素胶囊600mg,采用液相色谱-质谱法(1iquid chromatography-masss pectrography,LC-MS),测定血浆中不同时间点的药物浓度,用DAS程序计算药代动力学参数。结果口服苦参素胶囊后其在慢性乙肝患者及健康受试者的体内过程均符合药代动力学二室模型,慢性乙肝患者和健康受试者的主要药代动力学参数分别为T1/2(Ka)(0.91±0.50),(0.99±0.42)h;T1/2(α)(1.40±1.17),(1.35±0.74)h;T1/2(β)(2.41±2.14),(2.15±1.51)h;tmax(2.30±0.89),(2.50±1.03)h;Cmax(396.78±67.86),(392.11±121.24)μg/L;V/F(8.94±13.42),(10.01±17.46)L/kg;AUC(0~12h)(1617.27±169.67),(1723.08±531.65)μg/L·h^-1;C1/F(2.02±1.34),(2.30±1.69)L/h·kg^-1。经统计学处理,2组药代动力学参数均无显著性差异(P〉0.05)。结论苦参素胶囊在慢性乙肝患者和健康人体内的药代动力学过程无显著性差异。
Objective To study the pharmacokinetics of Oxymatrine capsules in patients with chronic hepatitis B. Methods A single oral dose of 600 mg of Oxymatrine capsules was given to 10 patients with chronic hepatitis B and 10 healthy male volunteers, respectively. Oxymatrine concentrations in plasma were determined by liquid chromatography-mass spectrography. Results The concentration-time curves of oxymatrine after oral adiministration accorded with two- compartment model . The main pharmacokinetic parameters were as follows, T1/2(Ka) (0. 91 ± 0.50), (0. 99±0.42) h ; T1/2(α) (1. 40±1.17), (1.35±0.74) h;T1/2(β) (2.41±2.14) ,(2.15+1.51) h;tmax(2. 30±0. 89) ,(2.50±1.03) h;Cmax(396.78±67.86), (392.11±121.24)μg/L;V/F (8.94 ±13.42), (10.01 ± 17.46) L/kg; AUC(0-12h) (1 617. 27 ± 169. 67 ), (1 723.08 ± 531. 65 ) μg/L · h^-1 ;C1/F (2.02± 1.34), (2.30±1.69) L/h · kg^-1. Conclusion No difference was found in the pharmacokinetics between the patients with chronic hepatitis B and normal control after single oral administration of Oxymatrine capsules( P 〉0.05).
出处
《河北医科大学学报》
CAS
2008年第1期62-65,共4页
Journal of Hebei Medical University
基金
河北省科学研究与发展计划指导项目(052761596)
关键词
苦参素
肝炎
乙型
慢性
药代动力学
oxymatrine
hepatitis B, chronic
pharmacokinetics